Medicine is a high-value, highly regulated product where most of the material never reaches the patient and some of what does reaches the environment. Making a kilogram of active ingredient generates far more waste than almost any other kind of chemical production, and the molecules that do their job in the body do not disappear afterwards. Both facts used to sit outside the commercial conversation. They are now moving into it, because what a pharmaceutical company puts into water, and how securely it can make and source its products, are becoming conditions of trade.
For years sustainability in pharma meant carbon targets and packaging tweaks reported once a year. It is becoming something with a balance-sheet line. Producers are about to pay for removing their residues from public wastewater, and the supply chains behind critical medicines are under political pressure to reshore and de-risk. For pharma the circular problem shows up at two ends at once: the factory that makes the molecule and the water that carries it away.
The product is the small part
Start with the material reality. Pharmaceutical manufacturing is among the most waste-intensive forms of chemical production, because the purity the regulator demands drives high volumes of solvent and reagent per unit of finished product. Life-cycle work on active-ingredient plants attributes the large majority of that waste to solvents. Primary packaging is mostly single-use by design and constrained by good manufacturing practice, so it resists ordinary recycling. And the active ingredient itself does not end at the patient: a measurable share passes through the body and through sewage treatment into surface water, where antidepressants, painkillers and hormones are detected at levels that affect aquatic life. In material terms a medicine is a small, high-value core wrapped in waste at the factory and followed by residue at the point of use.
The supply chain
- Stage 1Feedstocks and solvents
- Stage 2API synthesis (often India and China)
- Stage 3Formulation and fill-finish
- Stage 4Packaging and serialisation
- Stage 5Distribution and cold chain
- Stage 6Pharmacy and hospital
- Stage 7Patient use
- Stage 8Excretion and disposal into wastewater
Value
Value sits in the patented molecule and the finished product, roughly stages two to four.
Risk
Risk sits at the two ends. Concentrated active-ingredient supply at the front, and residue and waste cost at the back.
Your role
For the CEO, CFO or owner
The wastewater Extended Producer Responsibility (EPR) is a new recurring operating cost tied to your product portfolio, and supply concentration is a continuity risk to the medicines that earn most of your revenue. Both are balance-sheet questions before they are sustainability ones. The variable you control is whether you build readiness ahead of the 2027 transposition and the 2028 Extended Producer Responsibility (EPR) start, or absorb the cost and the risk under deadline. These are de-risking investments, not green spend.
For operations, quality and procurement managers
This is where the pressures become concrete. Operations and quality own the solvent and packaging streams and the feasibility of recovery within Good Manufacturing Practice (GMP). Procurement owns the active-ingredient supply map and its concentration risk. Sustainability owns the data the wastewater Extended Producer Responsibility (EPR) will demand on what is placed on the market. The internal conversation lands hardest when it shows up in a process or supplier decision, not in the annual report.
For people on the floor and in the lab
You see where solvent is wasted and where a process could run cleaner, often before it reaches a report. The most useful thing you can do is make those observations visible to the people who own the budgets, because the regulations arriving now turn what looked like minor inefficiency into measurable cost. Process and green-chemistry suggestions that once seemed like nice-to-haves now have a business case behind them.
The trap is treating it as one problem
The common failure in pharma is to fold all of this into a single sustainability programme and a single budget line. Wastewater Extended Producer Responsibility (EPR), supply resilience and manufacturing waste are different goals with different owners, different data and different investment. Pay the wastewater charge and you have done nothing for active-ingredient security or for the solvent leaving your plant. Reshore production and you may still face the residue bill and the waste-export cost. They connect, but they are not the same, and treating them as one is how a pharmaceutical company pays the treatment levy and still carries an unsecured supply chain and an exported waste stream. So the first question, before the spending starts, is which pressure is actually binding. For a marketing-authorisation holder selling broadly into the EU, the wastewater Extended Producer Responsibility (EPR) may lead. For a maker of critical generics, supply resilience may matter more. For a solvent-heavy manufacturing site, the waste and recovery case may come first. They point in compatible directions, but the sequence and the investment differ.
The pressure with a deadline: wastewater Extended Producer Responsibility (EPR)
The first force is regulatory and dated. The recast Urban Wastewater Treatment Directive, Directive (EU) 2024/3019, introduces extended producer responsibility for human medicines and cosmetics for the first time. Because pharmaceutical and cosmetic residues are the dominant source of the micropollutants that ordinary treatment leaves behind, producers will fund the additional quaternary treatment stage that removes them. Producers cover at least 80% of those investment and operating costs, complemented by national financing, under the polluter-pays principle. Member States transpose the directive by 31 July 2027, and the obligation applies to in-scope companies from 31 December 2028, with quaternary treatment rolled out in larger plants through to 2045. Industry estimates of the collective bill run into the order of a billion euro per Member State.
- Directive (EU) 2024/3019
- Producers cover at least 80% of quaternary treatment cost
- Transpose by 31 Jul 2027
- Extended Producer Responsibility (EPR) applies from 31 Dec 2028
- Exemptions under Art. 9: under 1 t/year or readily biodegradable
For a manufacturer or marketing-authorisation holder this is a new, recurring operating cost tied to the products it sells, not a one-off filing. It also rewards reformulation, since a molecule that is readily biodegradable or sold below the volume threshold can fall outside the charge. The directive quietly turns the environmental design of the molecule into a cost variable, not only a reputational one.
The pressure without a date: supply resilience
The second force is slower and structural. Europe makes few of its own active ingredients and imports the majority from a small number of producers in India and China, and recent shortages of medicines as basic as antibiotics have made that dependency a political problem. The Critical Medicines Act, proposed in March 2025 and brought to a provisional agreement between the Council and Parliament in May 2026, aims to reshore and diversify production of essential medicines through joint procurement, financing for EU manufacturing and contingency stocks. More than half of recent critical shortages have been linked to manufacturing problems compounded by that concentration of supply. Securing reliable, compliant production is becoming a question of where and how medicines are made, which is a circular sourcing and resilience question in all but name. The same investment that secures supply, in cleaner local manufacturing and recovered process inputs, also reduces the waste and emissions the other pressures are about to price.
- Critical Medicines Act proposed Mar 2025
- Provisional Council and Parliament deal May 2026
- Over 50% of recent critical shortages linked to manufacturing issues
- API supply concentrated in India and China
Four perspectives
European Union
The EU is pricing the externality and reshoring the supply at the same time. The wastewater directive puts the cost of micropollutant removal onto producers, while the Critical Medicines Act pushes production back inside the bloc. Together they reward companies that make medicines more cleanly and locally, and they raise the cost for companies that treat both as someone else's problem.
International
Outside the EU the same forces appear unevenly. Many markets have no producer charge for pharmaceutical residues, so a molecule designed for EU compliance carries an advantage everywhere it is sold, while companies selling only into lighter-touch markets feel less immediate pressure. The concentration of global active-ingredient supply is a shared exposure regardless of market, so resilience is becoming a worldwide sourcing question even where the environmental rules lag.
Netherlands
The Netherlands moved before the mandate. Since 2016 the Ketenaanpak Medicijnresten uit Water has brought government, water companies, hospitals, pharmacies and producers together to cut pharmaceutical residues in water, with RIVM estimating at least 190,000 kg reaching surface water each year. Dutch water authorities have piloted advanced treatment ahead of the EU requirement, and the country's role as a distribution and logistics hub places it at the consumption-and-water end of the chain. For companies selling into the Netherlands the collaborative infrastructure already exists, and the Extended Producer Responsibility (EPR) now formalises who pays.
Ireland
Ireland sits at the opposite end of the chain, as one of the world's largest pharmaceutical manufacturing and export bases. The circular pressure here is industrial. Pharmaceutical manufacturing is highly solvent-intensive, and a large share of the country's hazardous waste, much of it solvent, has historically been exported for treatment rather than recovered at home. The live opportunity is Good Manufacturing Practice (GMP)-standard solvent recovery inside Ireland, modelled on operations already running in France and Germany, which would turn an exported waste problem into recovered value and local resilience. The Critical Medicines Act reshoring push also points more production toward established hubs like Ireland, which raises the stakes on making that production clean.
Readiness check
Five statements. Count the ones you can honestly answer yes to. Fewer yeses means an earlier starting point, not a failing grade.
- 1. We know which of our products fall in scope of the wastewater Extended Producer Responsibility (EPR) and roughly what the contribution could cost.
- 2. We have a current map of where our active ingredients are made and how concentrated that supply is.
- 3. We can account for our major solvent and process-waste streams and what happens to them.
- 4. Environmental risk and biodegradability are considered in how we design or select products, not only at registration.
- 5. Unused-product take-back and safe disposal run through a structured route rather than being left to chance.
Answer all five statements to see your readout.
Where to start
If: You make active ingredients or finished product · Then: The solvent-recovery and green-chemistry case is your fastest lever. Start there.
If: You hold marketing authorisations and sell into the EU · Then: The wastewater Extended Producer Responsibility (EPR) exposure is your first question. Map your in-scope portfolio.
If: You run hospital or pharmacy procurement · Then: Take-back and safe disposal is where you reduce residue at the cheapest point.
If: You sit in policy or a water authority · Then: The question is shared infrastructure and who carries the cost, so producers and the public system are not working against each other.
Circular levers
Green chemistry and solvent recovery
Redesigning synthesis to cut solvent use, and recovering spent solvent to Good Manufacturing Practice (GMP) standard for reuse rather than export or incineration. It lowers manufacturing waste and reduces reliance on imported inputs at the same time.
Designing the molecule and packaging for the environment
Designing for biodegradability and lower environmental risk, and rethinking single-use primary packaging within Good Manufacturing Practice (GMP) limits. Under the wastewater Extended Producer Responsibility (EPR) a more biodegradable molecule can reduce or remove the producer charge, so environmental design becomes a cost lever.
Take-back and safe disposal
Structured collection of unused medicines through pharmacies keeps active ingredients out of water and out of landfill, and is the cheapest point to intervene in the residue problem.
Device remanufacturing and reuse
Inhalers, autoinjectors and diagnostic devices designed for return and refurbishment, recovering both materials and value.
Resilient, cleaner manufacturing
Continuous and biological production routes that use far less solvent than traditional bulk synthesis, serving resilience and waste goals together.
The streams that were a disposal cost or an imported risk become either recovered value or reduced exposure, and the design choices that satisfy the wastewater rule also lower the cost of making and sourcing the product.
Where Circular Intelligence works
Circular Intelligence works at the point where pharmaceutical sustainability becomes an operational and financial decision rather than a reporting line, and the sector is one of the clearest places that shift is now landing. The wastewater Extended Producer Responsibility (EPR) becomes a reformulation and design question with a cost case attached. Solvent and process waste becomes a recovery business case rather than an export line. Active-ingredient concentration becomes a sourcing and resilience strategy a board can act on. The work also means being clear about which of those pressures is really driving the decision, so capital goes where it counts. This is territory we work in directly, in pharma and across regulated manufacturing and chemicals.